Item 8.01 - Other Events
On December 3, 2021, Amicus Therapeutics, Inc. (the "Company") issued a press
release announcing that the European Medicines Agency validated the Marketing
Authorization Applications for AT-GAA, the Company's investigational
two-component therapy for the treatment of Pompe disease. A copy of this press
release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No. Description
99.1 Press Release dated December 3, 2021
Cover Page Interactive Data File (embedded within the Inline
104 XBRL document)
© Edgar Online, source Glimpses